COMP <GO>
PIII vs CCM // EV/EBITDA & P/E VALUATION
P3 Health Partners Inc. (Class A) (NASDAQ) VS. Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A) (NYSE) • 15-METRIC TALLY: PIII 3
— CCM 3
■ METRIC PARITY
LAST: $4.20 (+4.22%) • MKT CAP: $30.5M
valuation
—
CCM — Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)
ROARABLE E • RQD 22/100
LAST: $3.66 (-4.93%) • MKT CAP: $15.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PIII VS. CCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PIII | CCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 5.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -18.50% | -57.60% | +39.10 | PIII | /operating-margins <GO> |
| Net Profit Margin | -10.10% | -20.40% | +10.30 | PIII | /net-margins <GO> |
| Revenue Growth (YoY) | -2.80% | 26.60% | -29.40 | CCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | CCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.2 | 47.6 | -15.39 | CCM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.5M | $15.9M | $14.6M | PIII | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PIII REV | CCM REV | PIII GROSS % | CCM GROSS % | PIII FCF | CCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.46B | $65.0M | — | 5.7% | -$91.2M | -$36.9M |
| FY 2024 | $1.50B | $51.3M | — | -21.1% | -$110.1M | -$75.1M |
| FY 2023 | $1.27B | $73.3M | — | — | -$76.0M | -$38.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PIII // BETA —
CCM // BETA —